Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB002.1T with Chemotherapy in Advanced Solid Tumors
NCT04802980Phase 1Unknown
- Sponsor
- Huabo Biopharm
- Start
- Apr 2020
- Primary completion
- Jul 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of HB002.1T in solid tumor (advanced stage), gastric cancer (GC), ovarian cancer and 7 more (3 arms), sponsored by Huabo Biopharm. Primary endpoint: Maximum Tolerated Dose at 3 weeks. Status: unknown.
02
Drugs
HB002.1T
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)ovarian cancerCervical Cancer (CC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04802980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802980.